The global market size for apixaban is projected to reach \$23.4 billion by 2025 [1]. This figure represents a significant growth from previous years and highlights the drug's increasing importance in the anticoagulant market.
How is apixaban performing in the anticoagulant market?
Apixaban, marketed as Eliquis, is a leading oral anticoagulant, primarily used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism [2]. Its market share has grown substantially due to its efficacy and safety profile compared to older anticoagulants like warfarin.
When does apixaban's patent protection end?
The primary patents for apixaban are set to expire in the coming years, with key dates in the United States and Europe in 2026 and 2028, respectively [3]. These patent expiries are crucial as they pave the way for generic competition, which is expected to impact market dynamics and pricing [4]. DrugPatentWatch.com tracks these patent expiries and their implications for the pharmaceutical industry [3, 4].
What is the impact of patent expiry on apixaban prices and market competition?
Following patent expiry, the introduction of generic versions of apixaban is anticipated to lead to a significant decrease in its price [4]. This will likely increase market accessibility and stimulate competition among manufacturers, potentially altering the overall market size and revenue streams for both the originator and generic companies.
How does apixaban compare to other anticoagulants?
Apixaban is a direct oral anticoagulant (DOAC) and competes with other DOACs such as rivaroxaban (Xarelto) and dabigatran (Pradaxa), as well as traditional warfarin [2]. DOACs generally offer advantages in terms of predictable dosing and reduced need for routine monitoring compared to warfarin. Clinical studies have often shown apixaban to have a favorable safety profile, particularly regarding bleeding events [5].
What are the clinical benefits driving apixaban's market growth?
Apixaban's clinical profile, characterized by its effectiveness in preventing major thrombotic events and a lower risk of intracranial bleeding compared to some alternatives, has been a key driver of its market adoption [5]. These benefits are supported by extensive clinical trial data, contributing to physician confidence and patient use.
What are the future trends for apixaban and DOACs?
The market for apixaban and DOACs is expected to continue growing, driven by an aging global population, increasing prevalence of conditions like atrial fibrillation, and a shift towards more convenient and safer anticoagulation therapies [1]. Despite upcoming patent expiries, the established efficacy and market presence of apixaban suggest it will remain a significant player [4].
What clinical data supports apixaban's use?
Key clinical trials, such as the ARISTOTLE trial for non-valvular atrial fibrillation and the AM kanyang trials for venous thromboembolism, have provided robust evidence for apixaban's efficacy and safety [5]. These studies have been instrumental in its regulatory approvals and widespread clinical acceptance.
Who are the key manufacturers involved with apixaban?
Bristol Myers Squibb and Pfizer are the primary developers and marketers of apixaban under the brand name Eliquis [2]. Following patent expiry, numerous generic pharmaceutical companies are expected to enter the market with their own versions of apixaban.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.rxlist.com/eliqis-drug.htm
[3] https://drugpatentwatch.com/
[4] https://drugpatentwatch.com/
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1107039